Search results for: 'Tissue Diagnostics Market,'

Robot-assisted surgery offers significant promise in driving down treatment costs and addressing the healthcare industry’s increasing burden of lifestyle-related diseases and demand for affordable care. Next-generation surgical robotics technology and surgical navigation systems complement and extend surgeons’ ability to minimize surgical variabili...

23 Jun 2023  |  Global  |  Market Research

Global Tissue-engineered Skin Substitute Growth Opportunities

Breakthrough Technologies and Competitive Intensity Drive Innovation

Infographics

×

Rising incidents of burn injuries, road accidents, and other trauma injuries, along with increasing cases of chronic wounds, such as diabetic ulcers and venous ulcers, are boosting the global tissue-engineered skin substitutes (TESS) market. Moreover, the increasing number of surgical injuries, plastic surgeries, cosmetic surgeries, and other recon...

According to the National Institute of Health (NIH), there are more than 80 types of autoimmune diseases, of which less than 30 are diagnosable. Being 1 of the top 10 causes of death in the United States, there is a critical need in the market for the diagnosis and the treatment of both systemic diseases, such as lupus and rheumatoid arthritis, as ...

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, presenting opportunities for innovation. There has been a...

This Frost & Sullivan research service discusses advances in AI integration in Molecular Diagnostics, highlights key advantages of incorporating AI in the diagnostics workflow and roadblocks that have prevented it from becoming mainstream. While AI is widely used in radiology- and pathology-based diagnostics, its adoption is gradually increasing in...

The concept of companion diagnostics (CDx) was developed when researchers realized that even potent drugs only had an efficacy between 25% and 60%, the lowest being in oncology. Therefore, a clinical pharmacogenetic assay became important to distinguish patients more likely to respond to a drug or at a lesser risk of associated adverse pathophysiol...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...

19 Jun 2024  |  Global  |  Technology Research

Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024 2028

Leveraging integrated and point-of-care diagnostics with multiomics represents the most promising growth opportunity to advance molecular diagnostics for neurodegenerative diseases

Infographics

×

Neurodegenerative diseases (NDD) pose significant challenges to healthcare systems and affect millions of people worldwide, making early detection crucial. While the current diagnostic strategy is predominantly brain imaging techniques, it is not performed until symptoms are more pronounced. Subtle changes occurring in neural cells during early pro...

20 Jan 2025  |  Global  |  Market Research

Global Cardiac Biomarkers Diagnostics Industry, 2024-2029

Rising Prevalence of CVD and High Sensitivity POCT Driving Transformational Growth in Cardiac Biomarkers Diagnostics

Infographics

×

The global cardiac biomarkers diagnostics market is forecast to record robust growth with the increased prevalence of cardiovascular disease (CVD), multiplex biomarkers, advancements in diagnostic testing technology, higher POCT adoption rates, and an intensive focus on preventive healthcare. CVDs are a leading cause of mortality globally, highligh...